WCN26-7539 UNDERSTANDING THE IMPACT OF SGLT2 INHIBITORS IN TYPE 2 DIABETES MELLITUS WITH BIOPSY-PROVEN RENAL INVOLVEMENT

Read full text Summarise with VIRAT
Authors: Meritxell Ibernón, Montserrat Gomà Gallego, Ariel Tango, Oana Rap, Neus Rodríguez Farré, Pilar Ruíz, Ana Sánchez, Cristina Cabrera-López, Maru Navarro
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Type 2 diabetes mellitus (T2DM) leads to chronic kidney disease (CKD) in 30–40% of patients and is the major cause of end-stage renal disease (ESRD). The clinical course of diabetic kidney disease is highly heterogeneous, and discrepancies exist between clinical parameters and renal histology. Moreover, lesions of non-diabetic renal disease (NDRD) can coexist with diabetic nephropathy (DN). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve cardiorenal outcomes in CKD patients with and without diabetes, but their effect in biopsy-confirmed DN remains unclear.

Fields of Study & Subjects

Chronic Kidney Disease and Diabetes Diabetes Treatment and Management Acute Kidney Injury Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104641–104641
Publication date
25 March 2026
Language
EN